SG11201909359YA - Pharmaceutical composition comprising pde9 inhibitor - Google Patents
Pharmaceutical composition comprising pde9 inhibitorInfo
- Publication number
- SG11201909359YA SG11201909359YA SG11201909359YA SG11201909359YA SG 11201909359Y A SG11201909359Y A SG 11201909359YA SG 11201909359Y A SG11201909359Y A SG 11201909359YA SG 11201909359Y A SG11201909359Y A SG 11201909359YA
- Authority
- SG
- Singapore
- Prior art keywords
- eisai
- international
- tsukuba
- tice
- boulevard
- Prior art date
Links
- 229940076380 PDE9 inhibitor Drugs 0.000 title abstract 3
- RVEJWGYZBXCGGM-DNVCBOLYSA-N chembl2179094 Chemical compound C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=CC=CC=C1 RVEJWGYZBXCGGM-DNVCBOLYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 06 December 2018 (06.12.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo om HE ioo iflo ow (10) International Publication Number WO 2018/221546 Al TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (51) International Patent Classification: A61K 31/444 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/JP2018/020643 (22) International Filing Date: (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/513,690 01 June 2017 (01.06.2017) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 (JP). (72) Inventors: SCHUCK Edgar; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). LAI Robert; C/O Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL109SN (GB). SAVANT-LANDRY Ishani; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). REGE Bhaskar; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). MIYAMO- TO Mai; C/O Eisai Co., Ltd. Tsukuba Research Lab- oratories, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 3002635 (JP). KOTANI Sadaharu; C/O Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 (JP). HORIE Kanta; C/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 3002635 (JP). (74) Agent: HASEGAWA Yoshiki et al.; SOEI PATENT AND LAW FIRM, Marunouchi MY PLAZA (Meiji Yasuda Life Bldg.) 9th fl., 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1000005 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 30 May 2018 (30.05.2018) Published: — with international search report (Art. 21(3)) (54) Title: PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR 1-1 0 (57) : The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 hibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-y1)-1-(tetrahydrofuran-3-y1)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one or pharmaceu- C tically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762513690P | 2017-06-01 | 2017-06-01 | |
PCT/JP2018/020643 WO2018221546A1 (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising pde9 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909359YA true SG11201909359YA (en) | 2019-11-28 |
Family
ID=64455959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909359Y SG11201909359YA (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising pde9 inhibitor |
Country Status (12)
Country | Link |
---|---|
US (2) | US11484502B2 (en) |
EP (1) | EP3630113A4 (en) |
JP (1) | JP7293129B2 (en) |
KR (1) | KR20200010211A (en) |
CN (2) | CN116585316A (en) |
AU (1) | AU2018276566A1 (en) |
BR (1) | BR112019023557A2 (en) |
CA (1) | CA3059539A1 (en) |
MX (1) | MX2019013198A (en) |
RU (1) | RU2019135261A (en) |
SG (1) | SG11201909359YA (en) |
WO (1) | WO2018221546A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102627790B1 (en) | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Dementia treatment using a combination of pyrazoloquinoline derivatives and memantine |
WO2018221551A1 (en) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
JP7079777B2 (en) | 2017-06-01 | 2022-06-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dementia treatment agent by combined use of pyrazoloquinoline derivative and donepezil |
CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
JPH05132484A (en) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | Pyrazoloquinoline and pyrazolonaphthylidene derivative |
DK0760819T3 (en) | 1994-05-24 | 2000-10-09 | Hoffmann La Roche | Tricyclic dicarbonyl derivatives |
DE19642591A1 (en) | 1996-10-15 | 1998-04-16 | Basf Ag | New piperidine-ketocarboxylic acid derivatives, their production and use |
HN2002000317A (en) | 2001-11-02 | 2003-05-21 | Pfizer | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
WO2004014910A1 (en) | 2002-08-07 | 2004-02-19 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
DE102004004142A1 (en) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
US20060035920A1 (en) | 2004-05-28 | 2006-02-16 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
JP2006045118A (en) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | New pyrazoloquinolone derivative |
EP1925617B1 (en) | 2005-09-15 | 2012-11-14 | ASKA Pharmaceutical Co., Ltd. | Heterocyclic compound, and production process and use thereof |
TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
CN101466365A (en) | 2006-06-09 | 2009-06-24 | 惠氏公司 | Method for enhancing cognitive function |
CN101553491B (en) | 2006-12-13 | 2013-05-29 | Aska制药株式会社 | Quinoxaline derivative |
CN101557826A (en) | 2006-12-13 | 2009-10-14 | Aska制药株式会社 | Therapeutic agent for urinary tract disease |
MX2009011830A (en) | 2007-05-11 | 2009-11-13 | Pfizer | Amino-heterocyclic compounds. |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
AP2011005672A0 (en) | 2008-09-08 | 2011-04-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of CNS disorders. |
TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
AU2010219598A1 (en) | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
BRPI1011533A2 (en) | 2009-03-31 | 2016-03-29 | Boehringer Ingelheim Int | 1-heterocyclyl-15-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators. |
HUE038141T2 (en) | 2009-04-13 | 2018-10-29 | Theravance Biopharma R&D Ip Llc | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders |
US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
EP3053924A1 (en) | 2010-08-12 | 2016-08-10 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d]pyrimidin-4-one derivatives and their use as pde9a inhibitors |
RS54834B1 (en) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Pyrazoloquinoline compounds |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
JP6042060B2 (en) | 2011-09-26 | 2016-12-14 | サノフイ | Pyrazoloquinolinone derivatives, their preparation and therapeutic use |
PT2573073E (en) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
DK2769980T3 (en) | 2011-10-07 | 2016-04-11 | Eisai R&D Man Co Ltd | Pyrazolquinolinderivat as pde9 inhibitors |
WO2014163147A1 (en) * | 2013-04-05 | 2014-10-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Salt of pyrazoloquinoline derivative, and crystal thereof |
KR20180021693A (en) | 2015-05-07 | 2018-03-05 | 엑소반트 사이언시즈 게엠베하 | Compositions and methods for treating neurodegenerative diseases |
KR102627790B1 (en) | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Dementia treatment using a combination of pyrazoloquinoline derivatives and memantine |
WO2018221551A1 (en) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
JP7079777B2 (en) | 2017-06-01 | 2022-06-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dementia treatment agent by combined use of pyrazoloquinoline derivative and donepezil |
-
2018
- 2018-05-30 BR BR112019023557-4A patent/BR112019023557A2/en unknown
- 2018-05-30 CA CA3059539A patent/CA3059539A1/en active Pending
- 2018-05-30 WO PCT/JP2018/020643 patent/WO2018221546A1/en active Application Filing
- 2018-05-30 US US16/609,514 patent/US11484502B2/en active Active
- 2018-05-30 RU RU2019135261A patent/RU2019135261A/en unknown
- 2018-05-30 EP EP18809656.4A patent/EP3630113A4/en active Pending
- 2018-05-30 CN CN202310559688.6A patent/CN116585316A/en active Pending
- 2018-05-30 MX MX2019013198A patent/MX2019013198A/en unknown
- 2018-05-30 SG SG11201909359Y patent/SG11201909359YA/en unknown
- 2018-05-30 JP JP2019559117A patent/JP7293129B2/en active Active
- 2018-05-30 CN CN201880027744.9A patent/CN110545812A/en active Pending
- 2018-05-30 AU AU2018276566A patent/AU2018276566A1/en active Pending
- 2018-05-30 KR KR1020197032163A patent/KR20200010211A/en not_active Application Discontinuation
-
2022
- 2022-06-03 US US17/831,863 patent/US20220378706A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019135261A3 (en) | 2021-09-08 |
CA3059539A1 (en) | 2018-12-06 |
AU2018276566A1 (en) | 2019-11-07 |
KR20200010211A (en) | 2020-01-30 |
CN110545812A (en) | 2019-12-06 |
JP7293129B2 (en) | 2023-06-19 |
WO2018221546A1 (en) | 2018-12-06 |
MX2019013198A (en) | 2020-01-20 |
EP3630113A1 (en) | 2020-04-08 |
US11484502B2 (en) | 2022-11-01 |
US20200078306A1 (en) | 2020-03-12 |
US20220378706A1 (en) | 2022-12-01 |
RU2019135261A (en) | 2021-07-09 |
BR112019023557A2 (en) | 2020-06-02 |
EP3630113A4 (en) | 2021-02-24 |
CN116585316A (en) | 2023-08-15 |
JP2020521726A (en) | 2020-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909359YA (en) | Pharmaceutical composition comprising pde9 inhibitor | |
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201907034PA (en) | Methods of treating influenza | |
SG11201901594RA (en) | Cell suspension for use in the treatment of lower extremity peripheral artery disease | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201901868VA (en) | Breathable films with microbial barrier properties | |
SG11201810161RA (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
SG11201903806RA (en) | Antimicrobial gas releasing agents and systems and methods for using the same | |
SG11201908857QA (en) | Methods for the treatment of inflammation and inflammatory conditions | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808539WA (en) | Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201810192TA (en) | Antibacterial compositions | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201908472VA (en) | Compositions and methods for activating nk cells | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201908513RA (en) | Peptides for treatment of diabetes |